BlinkLab Ltd
ASX:BB1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BlinkLab Ltd
Stock-Based Compensation
BlinkLab Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BlinkLab Ltd
ASX:BB1
|
Stock-Based Compensation
AU$1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
4DMedical Ltd
ASX:4DX
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pro Medicus Ltd
ASX:PME
|
Stock-Based Compensation
AU$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Alcidion Group Ltd
ASX:ALC
|
Stock-Based Compensation
AU$134k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Artrya Ltd
ASX:AYA
|
Stock-Based Compensation
AU$2.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
164%
|
CAGR 10-Years
N/A
|
|
BlinkLab Ltd
Glance View
An app that turns an ordinary mobile phone into a device for conducting objective neurobehavioral tests could make it easier and more cost-effective to diagnose neurological disorders. The company is headquartered in Sydney, New South Wales. The company went IPO on 2024-04-04. The Company’s tests include eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response, which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The BlinkLab Device (BlinkLab Dx) consists of BlinkLab App, a mobile application for patients, caregivers and/or parents, effectively a front-end tool that helps collect test subjects’ information and responses to the BlinkLab Tests in real time (BlinkLab App), and BlinkLab Portal, which includes a fully built secure database and content management system (CMS) as well as experimenter’s portal that allows for full customization of the neurometric tests as well as data analysis, annotation and visualization tools (the BlinkLab Portal).
See Also
What is BlinkLab Ltd's Stock-Based Compensation?
Stock-Based Compensation
1.2m
AUD
Based on the financial report for Jun 30, 2025, BlinkLab Ltd's Stock-Based Compensation amounts to 1.2m AUD.
What is BlinkLab Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 1Y
310%
Over the last year, the Stock-Based Compensation growth was 310%.
